-transparent.png){kind=logo}
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. 1991
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
Division of Medical Oncology, Radboud University Hospital, Nijmegen, The Netherlands.
The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.
Related Publications
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
January 2007,
European journal of cancer (Oxford, England : 1990),
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
January 1993,
Cancer chemotherapy and pharmacology,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
January 2005,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
January 2014,
European journal of cancer (Oxford, England : 1990),
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
May 2000,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
February 1996,
Cancer,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
March 2002,
European journal of cancer (Oxford, England : 1990),
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
June 2017,
International journal of radiation oncology, biology, physics,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
July 2007,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D J Wagener, and
R Somers, and
A Santoro, and
J Verweij, and
P J Woll, and
G Blackledge, and
H J Schütte, and
M A Lentz, and
M van Glabbeke
June 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
